Avalyn Pharma Inc. — Form 8-K
Filed July 1, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
On June 29, 2026, Avalyn Pharma Inc. amended its sublease with CRISPR Therapeutics, Inc. to expand the leased premises at 105 West First Street, Boston from 8,774 sq ft to 13,708 sq ft. Under the amendment, future minimum lease payments increase by approximately $924,000 over the remaining lease term (ending January 31, 2029). Monthly rent for the expansion space ranges from $28,781.67 (through Jan 2027) to $30,534.47 (Feb 2028–Jan 2029). The amendment is contingent on master landlord consent and includes one additional parking pass.
Why this rating
Office expansion signals growth intent but $924k commitment is ~0.68% of $135.7M assets—routine operational need, not transformational.
Extracted items
- 1.01 material agreement
- 9.01 exhibits
View original filing on SEC.gov ↗
See more from July 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.